Physician profile
Brian David Wright
NPI 1164421525
$2,244.64
in general payments reported to CMS, 2019-2025
30 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $312 · 2021: $530 · 2022: $412 · 2023: $115 · 2024: $183 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $338.15 | 2019-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $225.35 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $173.45 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Welch Allyn | $168.41 | 2021 | |
| Baxter Healthcare | $168.41 | 2022 | |
| Amarin Pharma, INC. | $157.59 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $121.08 | 2025 | Voquezna |
| Astellas Pharma US INC | $104.69 | 2019-2025 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $104.37 | 2019-2021 | |
| Pfizer INC. | $75.37 | 2019-2022 | |
| Exact Sciences Corporation | $63.36 | 2023-2025 | Cologuard Collection Kit |
| Insulet Corporation | $61.24 | 2020 | |
| Covidien Lp | $46.56 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $41.50 | 2022 | |
| Lilly USA, LLC | $38.08 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $34.56 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.20 | 2021-2022 | |
| Abbott Laboratories | $34.15 | 2022-2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $33.80 | 2025 | Wavewriter Alpha Prime 16 |
| Radius Health, INC. | $33.43 | 2020 | |
| Idorsia Pharmaceuticals US INC | $31.45 | 2023-2024 | Quviviq |
| Dexcom, INC. | $24.90 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $20.98 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.47 | 2019 | |
| Amgen INC. | $20.27 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.93 | 2021 | |
| Glaxosmithkline, LLC. | $15.66 | 2023 | Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $12.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.31 | 2021 | |
| Aytu Biopharma, INC. | $12.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.